Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01896479
Title A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements Yes
Sponsors Exelixis
Indications

thyroid gland medullary carcinoma

Therapies

Cabozantinib

Age Groups: senior | adult
Covered Countries ITA | FRA | ESP | CAN

Additional content available in CKB BOOST